Atlas, Ferguson, and Hanson: On Free Speech at Stanford
What is the purpose of academic freedom?
Is it to allow all kinds of ideas to be expressed and explored, protecting even speech that people in the past considered hereticalâprotecting free expression that some people today would like to âcancelâ? Or is it to allow co-workers in the ideological minority to be personally and selectively disparaged with impunity?
The answer for some faculty at Stanford University would appear to be the latter.
In a recent meeting of the Stanford Faculty Senate, four professors (Joshua Landy, Stephen Monismith, David Palumbo-Liu and David Spiegel) presented and then subsequently published a farrago of falsehoods directed against various fellows of the Hoover Institution. Their complaint was, first, that the Hoover fellowsâ views were unapologetically conservative and, second, that they appeared antithetical to the majority of those of the Stanford communityâand were ther
Hoover Institution fellows Scott Atlas, Niall Ferguson, and Victor Davis Hanson were the subject of diatribes in a recent meeting of the Stanford Faculty Senate. The four professors who disparaged them (Joshua Landy, Stephen Monismith, David Palumbo-Liu and David Spiegel) then subsequently published a farrago of falsehoods directed against various fellows of the Hoover Institution. To wit: Their complaint was, first, that the Hoover fellows’ views were unapologetically conservative and,
Published: Jan 07, 2021
NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ) today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. ( Kleo ) that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo s laboratory facilities located in Science Park in New Haven, Connecticut and formed Biohaven Labs to serve as the integrated chemistry and discovery research arm of Biohaven. Biohaven Labs will continue several existing Kleo discovery partnerships, including with the Bill and Melinda Gates Foundation for the development of a Hyperimmune Globulin Mimic (HGM) for COVID-19 and PeptiDream for the development of immuno-oncology therapeutics.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the
acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo s laboratory facilities located in Science Park in New Haven, Connecticut and formed Biohaven Labs to serve as the integrated chemistry and discovery research arm of Biohaven. Biohaven Labs will continue several existing Kleo discovery partnerships, including with the Bill and Melinda Gates Foundation for the development of a Hyperimmune Globulin Mimic (HGM) for COVID-19 and PeptiDream for the development of immuno-oncology therapeutics.
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
- Acquires full ownership of Kleo Pharmaceuticals with two novel immune modulating platforms: the Multi-targeted Antibody Therapy Enhancer (MATE™) conjugation platform and Antibody Recruiting Molecule (ARM™) platform
- Enters into exclusive license agreement with Yale University for the development and commercialization of Yale s extracellular target degrader platform based on intellectual property derived from ground-breaking research in the laboratory of Professor David Spiegel
- Establishes Biohaven Labs at Science Park in New Haven to advance these three novel discovery platforms and several existing discovery partnerships to serve as an integrated chemistry and discovery research engine to complement Biohaven s late-stage clinical development and commercial expertise